Regeneron Pharmaceuticals Stock Forecast, Price & News

Regeneron Pharmaceuticals (NASDAQ:REGN) Frequently Asked Questions

Is Regeneron Pharmaceuticals a buy right now?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Regeneron Pharmaceuticals stock.
View analyst ratings for Regeneron Pharmaceuticals or view top-rated stocks.

How has Regeneron Pharmaceuticals' stock been impacted by COVID-19?

Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, REGN shares have increased by 33.7% and is now trading at $621.40.
View which stocks have been most impacted by COVID-19.

When is Regeneron Pharmaceuticals' next earnings date?

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, February 4th 2022.
View our earnings forecast for Regeneron Pharmaceuticals.

How can I listen to Regeneron Pharmaceuticals' earnings call?

Regeneron Pharmaceuticals will be holding an earnings conference call on Friday, February 4th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced its earnings results on Thursday, November, 4th. The biopharmaceutical company reported $15.37 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $9.81 by $5.56. The biopharmaceutical company earned $3.45 billion during the quarter, compared to analyst estimates of $2.80 billion. Regeneron Pharmaceuticals had a net margin of 51.65% and a trailing twelve-month return on equity of 50.38%. The firm's revenue was up 50.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $7.68 earnings per share.
View Regeneron Pharmaceuticals' earnings history.

What price target have analysts set for REGN?

18 analysts have issued 12 month target prices for Regeneron Pharmaceuticals' stock. Their forecasts range from $575.00 to $850.00. On average, they expect Regeneron Pharmaceuticals' stock price to reach $729.53 in the next year. This suggests a possible upside of 17.4% from the stock's current price.
View analysts' price targets for Regeneron Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Regeneron Pharmaceuticals' key executives?

Regeneron Pharmaceuticals' management team includes the following people:

• Leonard S. Schleifer, Co-President, Chief Executive Officer & Director
• George Damis Yancopoulos, Co-President, Director & Chief Scientific Officer (LinkedIn Profile)
• Patrice Gilooly, Senior VP-Quality Assurance & Operations
• Robert E. Landry, Chief Financial Officer & Executive VP-Finance (LinkedIn Profile)
• Neil Stahl, Executive VP-Research & Development

What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?

423 employees have rated Regeneron Pharmaceuticals CEO Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among Regeneron Pharmaceuticals' employees.

Who are some of Regeneron Pharmaceuticals' key competitors?

Some companies that are related to Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Repligen (RGEN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Novavax (NVAX), Arena Pharmaceuticals (ARNA) and Exelixis (EXEL).
View all of REGN's competitors.

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and salesforce.com (CRM).

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Russell Investments Group Ltd. (0.20%), Retirement Systems of Alabama (0.09%), Nordea Investment Management AB (0.05%), Royal London Asset Management Ltd. (0.03%), DNB Asset Management AS (0.03%) and State of Alaska Department of Revenue (0.02%). Company insiders that own Regeneron Pharmaceuticals stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van and Robert E Landry.
View institutional ownership trends for Regeneron Pharmaceuticals.

Which major investors are selling Regeneron Pharmaceuticals stock?

REGN stock was sold by a variety of institutional investors in the last quarter, including M&G Investment Management Ltd., DNB Asset Management AS, IBM Retirement Fund, Retirement Systems of Alabama, Nordea Investment Management AB, Kestra Advisory Services LLC, Clear Creek Financial Management LLC, and Royal London Asset Management Ltd.. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, George L Sing, George Yancopoulos, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, P Roy Vagelos, Plew Daniel P Van, and Robert E Landry.
View insider buying and selling activity for Regeneron Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Regeneron Pharmaceuticals stock?

REGN stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., AE Wealth Management LLC, Pendal Group Ltd, State of Alaska Department of Revenue, Lattice Capital Management LLC, Newman Dignan & Sheerar Inc., Baldwin Brothers LLC MA, and SevenBridge Financial Group LLC.
View insider buying and selling activity for Regeneron Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $621.40.

How much money does Regeneron Pharmaceuticals make?

Regeneron Pharmaceuticals has a market capitalization of $66.83 billion and generates $8.50 billion in revenue each year. The biopharmaceutical company earns $3.51 billion in net income (profit) each year or $62.63 on an earnings per share basis.

How many employees does Regeneron Pharmaceuticals have?

Regeneron Pharmaceuticals employs 9,123 workers across the globe.

Does Regeneron Pharmaceuticals have any subsidiaries?

The following companies are subsidiares of Regeneron Pharmaceuticals: Loop Road Holdings LLC, OSMR Holdings, OSMR International, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.

When was Regeneron Pharmaceuticals founded?

Regeneron Pharmaceuticals was founded in 1988.

What is Regeneron Pharmaceuticals' official website?

The official website for Regeneron Pharmaceuticals is www.regeneron.com.

Where are Regeneron Pharmaceuticals' headquarters?

Regeneron Pharmaceuticals is headquartered at 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591.

How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at (914) 847-7000, via email at [email protected], or via fax at 914-347-2113.